Summary

The global Choroidal Neovascularization Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Choroidal Neovascularization Drug Industry Forecast” looks at past sales and reviews total world Choroidal Neovascularization Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Choroidal Neovascularization Drug sales for 2025 through 2031. With Choroidal Neovascularization Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Choroidal Neovascularization Drug industry.
This Insight Report provides a comprehensive analysis of the global Choroidal Neovascularization Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Choroidal Neovascularization Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Choroidal Neovascularization Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Choroidal Neovascularization Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Choroidal Neovascularization Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Choroidal Neovascularization Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
AVMOC-001
BB-3
BBT-007
DG-3
Entolimod
EWA-001
Others
Segmentation by Application:
Clinic
Hospital
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Cellphire, Inc.
Chrysalis BioTherapeutics, Inc.
Cleveland BioLabs, Inc.
Cumberland Pharmaceuticals, Inc.
Diffusion Pharmaceuticals Inc.
Eli Lilly and Company
GNI Group Ltd.
Humanetics Corporation
INSYS Therapeutics, Inc.
Meabco A/S
Neumedicines Inc.
Onconova Therapeutics, Inc.
PharmaIN Corporation
Pluristem Therapeutics Inc.
ProCertus BioPharm Inc.
RDD Pharma Ltd.
RedHill Biopharma Ltd.
RxBio, Inc.
Soligenix, Inc.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Choroidal Neovascularization Drug market?
What factors are driving Choroidal Neovascularization Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Choroidal Neovascularization Drug market opportunities vary by end market size?
How does Choroidal Neovascularization Drug break out by Type, by Application?

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Choroidal Neovascularization Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Choroidal Neovascularization Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Choroidal Neovascularization Drug by Country/Region, 2020, 2024 & 2031
2.2 Choroidal Neovascularization Drug Segment by Type
2.2.1 AVMOC-001
2.2.2 BB-3
2.2.3 BBT-007
2.2.4 DG-3
2.2.5 Entolimod
2.2.6 EWA-001
2.2.7 Others
2.3 Choroidal Neovascularization Drug Sales by Type
2.3.1 Global Choroidal Neovascularization Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Choroidal Neovascularization Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Choroidal Neovascularization Drug Sale Price by Type (2020-2025)
2.4 Choroidal Neovascularization Drug Segment by Application
2.4.1 Clinic
2.4.2 Hospital
2.4.3 Others
2.5 Choroidal Neovascularization Drug Sales by Application
2.5.1 Global Choroidal Neovascularization Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Choroidal Neovascularization Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Choroidal Neovascularization Drug Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Choroidal Neovascularization Drug Breakdown Data by Company
3.1.1 Global Choroidal Neovascularization Drug Annual Sales by Company (2020-2025)
3.1.2 Global Choroidal Neovascularization Drug Sales Market Share by Company (2020-2025)
3.2 Global Choroidal Neovascularization Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Choroidal Neovascularization Drug Revenue by Company (2020-2025)
3.2.2 Global Choroidal Neovascularization Drug Revenue Market Share by Company (2020-2025)
3.3 Global Choroidal Neovascularization Drug Sale Price by Company
3.4 Key Manufacturers Choroidal Neovascularization Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Choroidal Neovascularization Drug Product Location Distribution
3.4.2 Players Choroidal Neovascularization Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Choroidal Neovascularization Drug by Geographic Region
4.1 World Historic Choroidal Neovascularization Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Choroidal Neovascularization Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Choroidal Neovascularization Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Choroidal Neovascularization Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Choroidal Neovascularization Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Choroidal Neovascularization Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Choroidal Neovascularization Drug Sales Growth
4.4 APAC Choroidal Neovascularization Drug Sales Growth
4.5 Europe Choroidal Neovascularization Drug Sales Growth
4.6 Middle East & Africa Choroidal Neovascularization Drug Sales Growth
5 Americas
5.1 Americas Choroidal Neovascularization Drug Sales by Country
5.1.1 Americas Choroidal Neovascularization Drug Sales by Country (2020-2025)
5.1.2 Americas Choroidal Neovascularization Drug Revenue by Country (2020-2025)
5.2 Americas Choroidal Neovascularization Drug Sales by Type (2020-2025)
5.3 Americas Choroidal Neovascularization Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Choroidal Neovascularization Drug Sales by Region
6.1.1 APAC Choroidal Neovascularization Drug Sales by Region (2020-2025)
6.1.2 APAC Choroidal Neovascularization Drug Revenue by Region (2020-2025)
6.2 APAC Choroidal Neovascularization Drug Sales by Type (2020-2025)
6.3 APAC Choroidal Neovascularization Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Choroidal Neovascularization Drug by Country
7.1.1 Europe Choroidal Neovascularization Drug Sales by Country (2020-2025)
7.1.2 Europe Choroidal Neovascularization Drug Revenue by Country (2020-2025)
7.2 Europe Choroidal Neovascularization Drug Sales by Type (2020-2025)
7.3 Europe Choroidal Neovascularization Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Choroidal Neovascularization Drug by Country
8.1.1 Middle East & Africa Choroidal Neovascularization Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Choroidal Neovascularization Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Choroidal Neovascularization Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Choroidal Neovascularization Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Choroidal Neovascularization Drug
10.3 Manufacturing Process Analysis of Choroidal Neovascularization Drug
10.4 Industry Chain Structure of Choroidal Neovascularization Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Choroidal Neovascularization Drug Distributors
11.3 Choroidal Neovascularization Drug Customer
12 World Forecast Review for Choroidal Neovascularization Drug by Geographic Region
12.1 Global Choroidal Neovascularization Drug Market Size Forecast by Region
12.1.1 Global Choroidal Neovascularization Drug Forecast by Region (2026-2031)
12.1.2 Global Choroidal Neovascularization Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Choroidal Neovascularization Drug Forecast by Type (2026-2031)
12.7 Global Choroidal Neovascularization Drug Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Cellphire, Inc.
13.1.1 Cellphire, Inc. Company Information
13.1.2 Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Cellphire, Inc. Main Business Overview
13.1.5 Cellphire, Inc. Latest Developments
13.2 Chrysalis BioTherapeutics, Inc.
13.2.1 Chrysalis BioTherapeutics, Inc. Company Information
13.2.2 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Chrysalis BioTherapeutics, Inc. Main Business Overview
13.2.5 Chrysalis BioTherapeutics, Inc. Latest Developments
13.3 Cleveland BioLabs, Inc.
13.3.1 Cleveland BioLabs, Inc. Company Information
13.3.2 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Cleveland BioLabs, Inc. Main Business Overview
13.3.5 Cleveland BioLabs, Inc. Latest Developments
13.4 Cumberland Pharmaceuticals, Inc.
13.4.1 Cumberland Pharmaceuticals, Inc. Company Information
13.4.2 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Cumberland Pharmaceuticals, Inc. Main Business Overview
13.4.5 Cumberland Pharmaceuticals, Inc. Latest Developments
13.5 Diffusion Pharmaceuticals Inc.
13.5.1 Diffusion Pharmaceuticals Inc. Company Information
13.5.2 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Diffusion Pharmaceuticals Inc. Main Business Overview
13.5.5 Diffusion Pharmaceuticals Inc. Latest Developments
13.6 Eli Lilly and Company
13.6.1 Eli Lilly and Company Company Information
13.6.2 Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolios and Specifications
13.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Eli Lilly and Company Main Business Overview
13.6.5 Eli Lilly and Company Latest Developments
13.7 GNI Group Ltd.
13.7.1 GNI Group Ltd. Company Information
13.7.2 GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.7.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 GNI Group Ltd. Main Business Overview
13.7.5 GNI Group Ltd. Latest Developments
13.8 Humanetics Corporation
13.8.1 Humanetics Corporation Company Information
13.8.2 Humanetics Corporation Choroidal Neovascularization Drug Product Portfolios and Specifications
13.8.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Humanetics Corporation Main Business Overview
13.8.5 Humanetics Corporation Latest Developments
13.9 INSYS Therapeutics, Inc.
13.9.1 INSYS Therapeutics, Inc. Company Information
13.9.2 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 INSYS Therapeutics, Inc. Main Business Overview
13.9.5 INSYS Therapeutics, Inc. Latest Developments
13.10 Meabco A/S
13.10.1 Meabco A/S Company Information
13.10.2 Meabco A/S Choroidal Neovascularization Drug Product Portfolios and Specifications
13.10.3 Meabco A/S Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Meabco A/S Main Business Overview
13.10.5 Meabco A/S Latest Developments
13.11 Neumedicines Inc.
13.11.1 Neumedicines Inc. Company Information
13.11.2 Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.11.3 Neumedicines Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Neumedicines Inc. Main Business Overview
13.11.5 Neumedicines Inc. Latest Developments
13.12 Onconova Therapeutics, Inc.
13.12.1 Onconova Therapeutics, Inc. Company Information
13.12.2 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.12.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Onconova Therapeutics, Inc. Main Business Overview
13.12.5 Onconova Therapeutics, Inc. Latest Developments
13.13 PharmaIN Corporation
13.13.1 PharmaIN Corporation Company Information
13.13.2 PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolios and Specifications
13.13.3 PharmaIN Corporation Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 PharmaIN Corporation Main Business Overview
13.13.5 PharmaIN Corporation Latest Developments
13.14 Pluristem Therapeutics Inc.
13.14.1 Pluristem Therapeutics Inc. Company Information
13.14.2 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.14.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Pluristem Therapeutics Inc. Main Business Overview
13.14.5 Pluristem Therapeutics Inc. Latest Developments
13.15 ProCertus BioPharm Inc.
13.15.1 ProCertus BioPharm Inc. Company Information
13.15.2 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.15.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 ProCertus BioPharm Inc. Main Business Overview
13.15.5 ProCertus BioPharm Inc. Latest Developments
13.16 RDD Pharma Ltd.
13.16.1 RDD Pharma Ltd. Company Information
13.16.2 RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.16.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 RDD Pharma Ltd. Main Business Overview
13.16.5 RDD Pharma Ltd. Latest Developments
13.17 RedHill Biopharma Ltd.
13.17.1 RedHill Biopharma Ltd. Company Information
13.17.2 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.17.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 RedHill Biopharma Ltd. Main Business Overview
13.17.5 RedHill Biopharma Ltd. Latest Developments
13.18 RxBio, Inc.
13.18.1 RxBio, Inc. Company Information
13.18.2 RxBio, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.18.3 RxBio, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 RxBio, Inc. Main Business Overview
13.18.5 RxBio, Inc. Latest Developments
13.19 Soligenix, Inc.
13.19.1 Soligenix, Inc. Company Information
13.19.2 Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
13.19.3 Soligenix, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Soligenix, Inc. Main Business Overview
13.19.5 Soligenix, Inc. Latest Developments
14 Research Findings and Conclusion

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Choroidal Neovascularization Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Choroidal Neovascularization Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of AVMOC-001
Table 4. Major Players of BB-3
Table 5. Major Players of BBT-007
Table 6. Major Players of DG-3
Table 7. Major Players of Entolimod
Table 8. Major Players of EWA-001
Table 9. Major Players of Others
Table 10. Global Choroidal Neovascularization Drug Sales by Type (2020-2025) & (K Pcs)
Table 11. Global Choroidal Neovascularization Drug Sales Market Share by Type (2020-2025)
Table 12. Global Choroidal Neovascularization Drug Revenue by Type (2020-2025) & ($ million)
Table 13. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2020-2025)
Table 14. Global Choroidal Neovascularization Drug Sale Price by Type (2020-2025) & (USD/Pcs)
Table 15. Global Choroidal Neovascularization Drug Sale by Application (2020-2025) & (K Pcs)
Table 16. Global Choroidal Neovascularization Drug Sale Market Share by Application (2020-2025)
Table 17. Global Choroidal Neovascularization Drug Revenue by Application (2020-2025) & ($ million)
Table 18. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2020-2025)
Table 19. Global Choroidal Neovascularization Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 20. Global Choroidal Neovascularization Drug Sales by Company (2020-2025) & (K Pcs)
Table 21. Global Choroidal Neovascularization Drug Sales Market Share by Company (2020-2025)
Table 22. Global Choroidal Neovascularization Drug Revenue by Company (2020-2025) & ($ millions)
Table 23. Global Choroidal Neovascularization Drug Revenue Market Share by Company (2020-2025)
Table 24. Global Choroidal Neovascularization Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 25. Key Manufacturers Choroidal Neovascularization Drug Producing Area Distribution and Sales Area
Table 26. Players Choroidal Neovascularization Drug Products Offered
Table 27. Choroidal Neovascularization Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 28. New Products and Potential Entrants
Table 29. Market M&A Activity & Strategy
Table 30. Global Choroidal Neovascularization Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 31. Global Choroidal Neovascularization Drug Sales Market Share Geographic Region (2020-2025)
Table 32. Global Choroidal Neovascularization Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 33. Global Choroidal Neovascularization Drug Revenue Market Share by Geographic Region (2020-2025)
Table 34. Global Choroidal Neovascularization Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 35. Global Choroidal Neovascularization Drug Sales Market Share by Country/Region (2020-2025)
Table 36. Global Choroidal Neovascularization Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 37. Global Choroidal Neovascularization Drug Revenue Market Share by Country/Region (2020-2025)
Table 38. Americas Choroidal Neovascularization Drug Sales by Country (2020-2025) & (K Pcs)
Table 39. Americas Choroidal Neovascularization Drug Sales Market Share by Country (2020-2025)
Table 40. Americas Choroidal Neovascularization Drug Revenue by Country (2020-2025) & ($ millions)
Table 41. Americas Choroidal Neovascularization Drug Sales by Type (2020-2025) & (K Pcs)
Table 42. Americas Choroidal Neovascularization Drug Sales by Application (2020-2025) & (K Pcs)
Table 43. APAC Choroidal Neovascularization Drug Sales by Region (2020-2025) & (K Pcs)
Table 44. APAC Choroidal Neovascularization Drug Sales Market Share by Region (2020-2025)
Table 45. APAC Choroidal Neovascularization Drug Revenue by Region (2020-2025) & ($ millions)
Table 46. APAC Choroidal Neovascularization Drug Sales by Type (2020-2025) & (K Pcs)
Table 47. APAC Choroidal Neovascularization Drug Sales by Application (2020-2025) & (K Pcs)
Table 48. Europe Choroidal Neovascularization Drug Sales by Country (2020-2025) & (K Pcs)
Table 49. Europe Choroidal Neovascularization Drug Revenue by Country (2020-2025) & ($ millions)
Table 50. Europe Choroidal Neovascularization Drug Sales by Type (2020-2025) & (K Pcs)
Table 51. Europe Choroidal Neovascularization Drug Sales by Application (2020-2025) & (K Pcs)
Table 52. Middle East & Africa Choroidal Neovascularization Drug Sales by Country (2020-2025) & (K Pcs)
Table 53. Middle East & Africa Choroidal Neovascularization Drug Revenue Market Share by Country (2020-2025)
Table 54. Middle East & Africa Choroidal Neovascularization Drug Sales by Type (2020-2025) & (K Pcs)
Table 55. Middle East & Africa Choroidal Neovascularization Drug Sales by Application (2020-2025) & (K Pcs)
Table 56. Key Market Drivers & Growth Opportunities of Choroidal Neovascularization Drug
Table 57. Key Market Challenges & Risks of Choroidal Neovascularization Drug
Table 58. Key Industry Trends of Choroidal Neovascularization Drug
Table 59. Choroidal Neovascularization Drug Raw Material
Table 60. Key Suppliers of Raw Materials
Table 61. Choroidal Neovascularization Drug Distributors List
Table 62. Choroidal Neovascularization Drug Customer List
Table 63. Global Choroidal Neovascularization Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 64. Global Choroidal Neovascularization Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Americas Choroidal Neovascularization Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 66. Americas Choroidal Neovascularization Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. APAC Choroidal Neovascularization Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 68. APAC Choroidal Neovascularization Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 69. Europe Choroidal Neovascularization Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 70. Europe Choroidal Neovascularization Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 71. Middle East & Africa Choroidal Neovascularization Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 72. Middle East & Africa Choroidal Neovascularization Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 73. Global Choroidal Neovascularization Drug Sales Forecast by Type (2026-2031) & (K Pcs)
Table 74. Global Choroidal Neovascularization Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 75. Global Choroidal Neovascularization Drug Sales Forecast by Application (2026-2031) & (K Pcs)
Table 76. Global Choroidal Neovascularization Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 77. Cellphire, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 78. Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 79. Cellphire, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 80. Cellphire, Inc. Main Business
Table 81. Cellphire, Inc. Latest Developments
Table 82. Chrysalis BioTherapeutics, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 83. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 84. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 85. Chrysalis BioTherapeutics, Inc. Main Business
Table 86. Chrysalis BioTherapeutics, Inc. Latest Developments
Table 87. Cleveland BioLabs, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 88. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 89. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 90. Cleveland BioLabs, Inc. Main Business
Table 91. Cleveland BioLabs, Inc. Latest Developments
Table 92. Cumberland Pharmaceuticals, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 93. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 94. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 95. Cumberland Pharmaceuticals, Inc. Main Business
Table 96. Cumberland Pharmaceuticals, Inc. Latest Developments
Table 97. Diffusion Pharmaceuticals Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 98. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 99. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 100. Diffusion Pharmaceuticals Inc. Main Business
Table 101. Diffusion Pharmaceuticals Inc. Latest Developments
Table 102. Eli Lilly and Company Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 103. Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 104. Eli Lilly and Company Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 105. Eli Lilly and Company Main Business
Table 106. Eli Lilly and Company Latest Developments
Table 107. GNI Group Ltd. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 108. GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 109. GNI Group Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 110. GNI Group Ltd. Main Business
Table 111. GNI Group Ltd. Latest Developments
Table 112. Humanetics Corporation Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 113. Humanetics Corporation Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 114. Humanetics Corporation Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 115. Humanetics Corporation Main Business
Table 116. Humanetics Corporation Latest Developments
Table 117. INSYS Therapeutics, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 118. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 119. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 120. INSYS Therapeutics, Inc. Main Business
Table 121. INSYS Therapeutics, Inc. Latest Developments
Table 122. Meabco A/S Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 123. Meabco A/S Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 124. Meabco A/S Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 125. Meabco A/S Main Business
Table 126. Meabco A/S Latest Developments
Table 127. Neumedicines Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 128. Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 129. Neumedicines Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 130. Neumedicines Inc. Main Business
Table 131. Neumedicines Inc. Latest Developments
Table 132. Onconova Therapeutics, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 133. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 134. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 135. Onconova Therapeutics, Inc. Main Business
Table 136. Onconova Therapeutics, Inc. Latest Developments
Table 137. PharmaIN Corporation Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 138. PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 139. PharmaIN Corporation Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 140. PharmaIN Corporation Main Business
Table 141. PharmaIN Corporation Latest Developments
Table 142. Pluristem Therapeutics Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 143. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 144. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 145. Pluristem Therapeutics Inc. Main Business
Table 146. Pluristem Therapeutics Inc. Latest Developments
Table 147. ProCertus BioPharm Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 148. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 149. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 150. ProCertus BioPharm Inc. Main Business
Table 151. ProCertus BioPharm Inc. Latest Developments
Table 152. RDD Pharma Ltd. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 153. RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 154. RDD Pharma Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 155. RDD Pharma Ltd. Main Business
Table 156. RDD Pharma Ltd. Latest Developments
Table 157. RedHill Biopharma Ltd. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 158. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 159. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 160. RedHill Biopharma Ltd. Main Business
Table 161. RedHill Biopharma Ltd. Latest Developments
Table 162. RxBio, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 163. RxBio, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 164. RxBio, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 165. RxBio, Inc. Main Business
Table 166. RxBio, Inc. Latest Developments
Table 167. Soligenix, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors
Table 168. Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications
Table 169. Soligenix, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 170. Soligenix, Inc. Main Business
Table 171. Soligenix, Inc. Latest Developments


List of Figures
Figure 1. Picture of Choroidal Neovascularization Drug
Figure 2. Choroidal Neovascularization Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Choroidal Neovascularization Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Choroidal Neovascularization Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Choroidal Neovascularization Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Choroidal Neovascularization Drug Sales Market Share by Country/Region (2024)
Figure 10. Choroidal Neovascularization Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of AVMOC-001
Figure 12. Product Picture of BB-3
Figure 13. Product Picture of BBT-007
Figure 14. Product Picture of DG-3
Figure 15. Product Picture of Entolimod
Figure 16. Product Picture of EWA-001
Figure 17. Product Picture of Others
Figure 18. Global Choroidal Neovascularization Drug Sales Market Share by Type in 2025
Figure 19. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2020-2025)
Figure 20. Choroidal Neovascularization Drug Consumed in Clinic
Figure 21. Global Choroidal Neovascularization Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 22. Choroidal Neovascularization Drug Consumed in Hospital
Figure 23. Global Choroidal Neovascularization Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 24. Choroidal Neovascularization Drug Consumed in Others
Figure 25. Global Choroidal Neovascularization Drug Market: Others (2020-2025) & (K Pcs)
Figure 26. Global Choroidal Neovascularization Drug Sale Market Share by Application (2024)
Figure 27. Global Choroidal Neovascularization Drug Revenue Market Share by Application in 2025
Figure 28. Choroidal Neovascularization Drug Sales by Company in 2025 (K Pcs)
Figure 29. Global Choroidal Neovascularization Drug Sales Market Share by Company in 2025
Figure 30. Choroidal Neovascularization Drug Revenue by Company in 2025 ($ millions)
Figure 31. Global Choroidal Neovascularization Drug Revenue Market Share by Company in 2025
Figure 32. Global Choroidal Neovascularization Drug Sales Market Share by Geographic Region (2020-2025)
Figure 33. Global Choroidal Neovascularization Drug Revenue Market Share by Geographic Region in 2025
Figure 34. Americas Choroidal Neovascularization Drug Sales 2020-2025 (K Pcs)
Figure 35. Americas Choroidal Neovascularization Drug Revenue 2020-2025 ($ millions)
Figure 36. APAC Choroidal Neovascularization Drug Sales 2020-2025 (K Pcs)
Figure 37. APAC Choroidal Neovascularization Drug Revenue 2020-2025 ($ millions)
Figure 38. Europe Choroidal Neovascularization Drug Sales 2020-2025 (K Pcs)
Figure 39. Europe Choroidal Neovascularization Drug Revenue 2020-2025 ($ millions)
Figure 40. Middle East & Africa Choroidal Neovascularization Drug Sales 2020-2025 (K Pcs)
Figure 41. Middle East & Africa Choroidal Neovascularization Drug Revenue 2020-2025 ($ millions)
Figure 42. Americas Choroidal Neovascularization Drug Sales Market Share by Country in 2025
Figure 43. Americas Choroidal Neovascularization Drug Revenue Market Share by Country (2020-2025)
Figure 44. Americas Choroidal Neovascularization Drug Sales Market Share by Type (2020-2025)
Figure 45. Americas Choroidal Neovascularization Drug Sales Market Share by Application (2020-2025)
Figure 46. United States Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. Canada Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 48. Mexico Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 49. Brazil Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 50. APAC Choroidal Neovascularization Drug Sales Market Share by Region in 2025
Figure 51. APAC Choroidal Neovascularization Drug Revenue Market Share by Region (2020-2025)
Figure 52. APAC Choroidal Neovascularization Drug Sales Market Share by Type (2020-2025)
Figure 53. APAC Choroidal Neovascularization Drug Sales Market Share by Application (2020-2025)
Figure 54. China Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. Japan Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. South Korea Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. Southeast Asia Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. India Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 59. Australia Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 60. China Taiwan Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 61. Europe Choroidal Neovascularization Drug Sales Market Share by Country in 2025
Figure 62. Europe Choroidal Neovascularization Drug Revenue Market Share by Country (2020-2025)
Figure 63. Europe Choroidal Neovascularization Drug Sales Market Share by Type (2020-2025)
Figure 64. Europe Choroidal Neovascularization Drug Sales Market Share by Application (2020-2025)
Figure 65. Germany Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. France Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. UK Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 68. Italy Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 69. Russia Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 70. Middle East & Africa Choroidal Neovascularization Drug Sales Market Share by Country (2020-2025)
Figure 71. Middle East & Africa Choroidal Neovascularization Drug Sales Market Share by Type (2020-2025)
Figure 72. Middle East & Africa Choroidal Neovascularization Drug Sales Market Share by Application (2020-2025)
Figure 73. Egypt Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. South Africa Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. Israel Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 76. Turkey Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 77. GCC Countries Choroidal Neovascularization Drug Revenue Growth 2020-2025 ($ millions)
Figure 78. Manufacturing Cost Structure Analysis of Choroidal Neovascularization Drug in 2025
Figure 79. Manufacturing Process Analysis of Choroidal Neovascularization Drug
Figure 80. Industry Chain Structure of Choroidal Neovascularization Drug
Figure 81. Channels of Distribution
Figure 82. Global Choroidal Neovascularization Drug Sales Market Forecast by Region (2026-2031)
Figure 83. Global Choroidal Neovascularization Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 84. Global Choroidal Neovascularization Drug Sales Market Share Forecast by Type (2026-2031)
Figure 85. Global Choroidal Neovascularization Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 86. Global Choroidal Neovascularization Drug Sales Market Share Forecast by Application (2026-2031)
Figure 87. Global Choroidal Neovascularization Drug Revenue Market Share Forecast by Application (2026-2031)